Company intelligence / Profile preview

TICEBA

Heidelberg, Baden-Württemberg, Germany

Ownership: Private
Employees: ~10
Development stage: Other

Overview

ABCB5-positive mesenchymal stem cells, developed and manufactured by TICEBA (now part of RHEACELL), have demonstrated anti-inflammatory and tissue-regenerative effects. Their cell therapy (AMESANAR®) is approved in Germany for chronic venous ulcers, and late-stage clinical trials (including pivotal Phase 3) are ongoing for epidermolysis bullosa (EBESANAR®); additional clinical studies are underway for other inflammation-driven and rare diseases.

Therapeutic areas: DermatologyEndocrinologyOphthalmologyCardiovascular
Modalities: Stem cell therapyMesenchymal stem cell therapyBiologic
Industry: Biotech

Partnerships

RHEACELL (primary development and clinical sponsor)

Beyond the preview

Go deeper on TICEBA.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TICEBA.

Explore the full profile